Gulf sovereign wealth funds are positioned for IPO windfalls, and the strategic payoff is resilient data and power in orbit.

Ateet Jayaswal’s blueprint for scaling hybrid human-AI work without breaking trust, privacy, or culture.

The Harvard biologist says he will test a swallowed “reprogramming” drug aimed at measurable immune, cognitive, and muscle gains.

The U.K. pharma giant lands its biggest deal in eight years to rebuild a trimmed cancer pipeline.

The latest AI listing race turns fundraising speed into a competitive weapon, with regulators and boards watching closely.

The orbital infrastructure thesis is the real IPO story, and it could force regulators and markets to rethink what space funding is for.

GSK’s new CEO commits to a major oncology bet: the $10.6bn Nuvalent deal deepens its late-stage pipeline for lung cancer.

The industry says aircraft can be evacuated in 90 seconds, but hand-luggage grabs and videos can turn that into disaster.

Her viral story ties “attitude” complaints to practical hiring friction and why it changes how managers screen.

A Bitcoin drop could erase the “Saylor Magic Premium” and trigger dilution and preferred payouts Strategy may not cover.

BYD bets China’s EV race keeps expanding, even as some expect domestic demand to cool further.

What one HK$110 million retail sale signals about how McDonald's is re-monetizing long-held property across Hong Kong.